We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-3.24%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$709M
AUM Growth
+$29.4M
Cap. Flow
+$90.1M
Cap. Flow %
12.71%
Top 10 Hldgs %
39.27%
Holding
116
New
17
Increased
23
Reduced
16
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$21.6M
2
NTLA icon
Intellia Therapeutics
NTLA
+$15.4M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$13.4M
4
NVCR icon
NovoCure
NVCR
+$11.3M
5
QURE icon
uniQure
QURE
+$8.42M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$10.9M
2
COF icon
Capital One
COF
+$8.75M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.67M
4
PYXS icon
Pyxis Oncology
PYXS
+$4.58M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.04%
2 Financials 5.11%
3 Real Estate 0.78%
4 Consumer Discretionary 0.07%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
51
Bolt Biotherapeutics
BOLT
$7.78M
$3.7M 0.52%
177,852
+11,162
+7% +$273K
BHVN icon
52
Biohaven
BHVN
$2.21B
$3.64M 0.51%
140,000
– –
ASLN
53
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$3.57M 0.5%
237,694
+96,685
+69% +$1.77M
GNFT
54
DELISTED
Genfit
GNFT
$3.4M 0.48%
1,040,636
-193,800
-16% -$710K
CVBF icon
55
CVB Financial
CVBF
$3.99B
$3.31M 0.47%
200,000
– –
USB icon
56
US Bancorp
USB
$99.6B
$3.31M 0.47%
100,000
– –
RAIN
57
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$3.22M 0.45%
3,740,341
– –
DSGN icon
58
Design Therapeutics
DSGN
$876M
$3.19M 0.45%
+1,350,000
New +$6.3M
LKFT
59
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$3.1M 0.44%
89,650
– –
ENZ
60
DELISTED
Enzo Biochem, Inc.
ENZ
$3.08M 0.43%
2,200,000
-100,000
-4% -$151K
RCKT icon
61
Rocket Pharmaceuticals
RCKT
$394M
$3.07M 0.43%
+150,000
New +$2.73M
CBAY
62
DELISTED
Cymabay Therapeutics
CBAY
$2.98M 0.42%
+200,000
New +$2.65M
LIAN
63
DELISTED
LianBio American Depositary Shares
LIAN
$2.68M 0.38%
1,800,000
+837,978
+87% +$1.6M
ELEV
64
DELISTED
Elevation Oncology
ELEV
$2.65M 0.37%
4,000,000
– –
ALGS icon
65
Aligos Therapeutics
ALGS
$34.9M
$2.49M 0.35%
133,162
– –
NKTR icon
66
Nektar Therapeutics
NKTR
$2.58B
$2.35M 0.33%
262,640
+253,333
+2,722% +$2.44M
LITS
67
Lite Strategy Inc
LITS
$30.9M
$2.29M 0.32%
326,084
-35,000
-10% -$230K
TNGX icon
68
Tango Therapeutics
TNGX
$4.41B
$2.25M 0.32%
200,000
– –
ACAD icon
69
Acadia Pharmaceuticals
ACAD
$5.03B
$2.08M 0.29%
+100,000
New +$2.72M
PDSB icon
70
PDS Biotechnology
PDSB
$43.4M
$2.02M 0.29%
400,000
+300,000
+300% +$1.64M
HRTX icon
71
Heron Therapeutics
HRTX
$92.9M
$1.91M 0.27%
1,850,000
– –
NEUP
72
Neuphoria Therapeutics
NEUP
$20.6M
$1.89M 0.27%
+58,333
New +$1.26M
EGRX
73
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.87M 0.26%
118,857
– –
ESPR
74
DELISTED
Esperion Therapeutics
ESPR
$1.81M 0.26%
1,850,000
– –
KRTX
75
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.69M 0.24%
+10,000
New +$1.88M
1 2
3
4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Tang Capital Management held 116 positions worth $709M, up 4.3% from $679M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management deployed $90.1M of net new capital in Q3 2023, opening 17 new positions and adding to 23 existing holdings. Its largest new stake was EQRx, Inc. Common Stock: 10,086,110 shares worth $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was bluebird bio, an estimated $10.9M trimmed.

  • Tang Capital Management's largest Q3 2023 buy was EQRx, Inc. Common Stock: 10,086,110 shares worth $22.4M.
  • Tang Capital Management added most to NovoCure in Q3 2023, an estimated $11.3M increase.
  • Tang Capital Management's biggest Q3 2023 reduction was bluebird bio, cutting an estimated $10.9M.
  • Tang Capital Management fully exited Capital One in Q3 2023, selling an estimated $8.75M.
  • Tang Capital Management's ten largest holdings make up 39% of its $709M portfolio in Q3 2023.
  • Tang Capital Management opened 17 new positions and closed 10 in Q3 2023.
  • Tang Capital Management's portfolio value rose 4.3% quarter-over-quarter to $709M.

Based on Tang Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.